Persistent Disease in Patients with Papillary Thyroid Carcinoma and Lymph Node Metastases After Surgery and Iodine-131 Ablation

[1]  J. Jonklaas,et al.  Outcomes of patients with differentiated thyroid carcinoma following initial therapy. , 2006, Thyroid : official journal of the American Thyroid Association.

[2]  J. Jimeno,et al.  Nodal yield, morbidity, and recurrence after central neck dissection for papillary thyroid carcinoma. , 2005, Surgery.

[3]  E. Baudin,et al.  Prognostic factors for persistent or recurrent disease of papillary thyroid carcinoma with neck lymph node metastases and/or tumor extension beyond the thyroid capsule at initial diagnosis. , 2005, The Journal of clinical endocrinology and metabolism.

[4]  I. Sugitani,et al.  A novel classification system for patients with PTC: addition of the new variables of large (3 cm or greater) nodal metastases and reclassification during the follow-up period. , 2004, Surgery.

[5]  M. Salvatori,et al.  Radio-guided Surgery for Lymph Node Recurrences of Differentiated Thyroid Cancer , 2003, World Journal of Surgery.

[6]  S. Libutti,et al.  Role of metastasectomy in the management of thyroid carcinoma: The NIH experience , 2003, Journal of surgical oncology.

[7]  R. Kloos,et al.  Nasolacrimal drainage system obstruction from radioactive iodine therapy for thyroid carcinoma. , 2002, The Journal of clinical endocrinology and metabolism.

[8]  E. Woltering,et al.  Gamma Probe–Guided Lymph Node Dissection (‘Gamma Picking’) in Differentiated Thyroid Carcinoma , 2002, Clinical nuclear medicine.

[9]  I. Witterick,et al.  Impact of nodal metastases on prognosis in patients with well-differentiated thyroid cancer. , 2002, Archives of otolaryngology--head & neck surgery.

[10]  R. Solans,et al.  Salivary and lacrimal gland dysfunction (sicca syndrome) after radioiodine therapy. , 2001, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[11]  H. Koppeschaar,et al.  Efficacy of high therapeutic doses of iodine-131 in patients with differentiated thyroid cancer and detectable serum thyroglobulin , 2001, European Journal of Nuclear Medicine.

[12]  M. Schlumberger,et al.  Papillary and follicular thyroid carcinoma. , 2000, Bailliere's best practice & research. Clinical endocrinology & metabolism.

[13]  B. de Keizer,et al.  Fixed dosage of 131I for remnant ablation in patients with differentiated thyroid carcinoma without pre-ablative diagnostic 131I scintigraphy , 2000, Nuclear medicine communications.

[14]  B. Cady.  Presidential address: beyond risk groups--a new look at differentiated thyroid cancer. , 1998, Surgery.

[15]  P. Ladenson,et al.  Prospective multicenter study of thyroiscarcinoma treatment: initial analysis of staging and outcome. National Thyroid Cancer Treatment Cooperative Study Registry Group. , 1998, Cancer.

[16]  S. Sherman.  Staging of thyroid carcinoma‐reply , 1998, Cancer.

[17]  P. Ladenson,et al.  Prospective multicenter study of thyroid carcinoma treatment , 1998 .

[18]  E. Baudin,et al.  Combination of radioiodine (131I) and probe-guided surgery for persistent or recurrent thyroid carcinoma. , 1998, The Journal of clinical endocrinology and metabolism.

[19]  R. Tsang,et al.  The effects of surgery, radioiodine, and external radiation therapy on the clinical outcome of patients with differentiated thyroid carcinoma , 1998, Cancer.

[20]  L. Sobin,et al.  TNM classification of malignant tumors, fifth edition (1997) , 1997, Cancer.

[21]  J. Shah,et al.  Impact of lymph node metastasis in differentiated carcinoma of the thyroid: A matched‐pair analysis , 1996, Head & neck.

[22]  S. Jhiang,et al.  Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. , 1994, The American journal of medicine.

[23]  H. Hundeshagen,et al.  Prognostic significance and surgical management of locoregional lymph node metastases in papillary thyroid cancer , 1994, World Journal of Surgery.

[24]  F. Cetani,et al.  Outcome of 309 patients with metastatic differentiated thyroid carcinoma treated with radioiodine , 1994, World Journal of Surgery.

[25]  E. Kaplan,et al.  Natural history, treatment, and course of papillary thyroid carcinoma. , 1990, The Journal of clinical endocrinology and metabolism.

[26]  B. Cady,et al.  An expanded view of risk-group definition in differentiated thyroid carcinoma. , 1988, Surgery.

[27]  S. McKinney,et al.  Papillary and follicular thyroid cancer. Prognostic factors in 1,578 patients. , 1987, The American journal of medicine.

[28]  L. Woolner,et al.  Papillary thyroid cancer treated at the Mayo Clinic, 1946 through 1970: initial manifestations, pathologic findings, therapy, and outcome. , 1986, Mayo Clinic proceedings.

[29]  E. Hjørting-Hansen.  Classification of malignant tumors , 1979 .

[30]  B. de Keizer,et al.  Prognostic significance of successful ablation with radioiodine of differentiated thyroid cancer patients. , 2005, European journal of endocrinology.

[31]  R. Hinze,et al.  Pattern of Nodal Metastasis for Primary and Reoperative Thyroid Cancer , 2001, World Journal of Surgery.

[32]  M. Noguchi,et al.  Papillary thyroid cancer and its surgical management. , 1992, Journal of surgical oncology.